MORE►
retinitis pigmentosa
Newly appointed business advisory board member Daniel Feller is "a pillar of the rare genetic disease community in Australia," according to Nacuity co-founder and CEO Halden Conner.
Nacuity Pharmaceuticals Expands Business Advisory Board
by Lance Murray | Feb 23, 2024
Newly appointed business advisory board member Daniel Feller is "a pillar of the rare genetic disease community in Australia," according to Nacuity co-founder and CEO Halden Conner.
by Kevin Cummings |
Jun 15, 2022
Nacuity Pharmaceuticals focuses on ocular diseases caused by oxidative stress in the retina, including age-related macular degeneration, glaucoma, and diabetic retinopathy. The $16.5M funding, led by the Foundation Fighting Blindness, will help advance two Nacuity clinical trials.
“This funding will help further our mission to develop a breakthrough treatment for retinitis pigmentosa and other serious blinding and chronic diseases," said Nacuity Chairman, CEO, and Co-founder Halden Conner.
MORE►
